Abstract
It has been demonstrated that sagopilone (ZK-EPO) has antitumor activity in human orthotopic glioma models in vitro and in vivo. The objective of this study was to evaluate the safety and efficacy of ZK-EPO in patients with pretreated, recurrent malignant gliomas. Fifteen patients with recurrent malignant gliomas who had received prior surgery, radiotherapy, and ≥2 lines of alkylating chemotherapy were recruited. ZK-EPO (16 mg/m2) was administered iv for 3 h every 21 days. The primary end point was six months progression-free survival (PFS-6); secondary end points were safety, toxicity, response rate, and median time to progression (TTP). Magnetic resonance imaging (MRI) evaluations were performed every two cycles and toxicity was evaluated at each cycle using common terminology criteria for adverse events (CTCAE 3.0). A median of four cycles was administered. The median TTP was 13 weeks. PFS-6 was achieved in five patients (33%), three with glioblastoma multiforme and two with anaplastic astrocytoma. The most common treatment-related adverse event was neuropathy, which occurred in 6/15 patients. ZK-EPO had an acceptable safety profile and clinically relevant activity in patients with pretreated, recurrent malignant gliomas.
Similar content being viewed by others
Bibliography
Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO et al (2006) Changing paradigms—an update on the multidisciplinary management of malignant glioma. Oncologist 11:165–180. doi:10.1634/theoncologist.11-2-165
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. doi:10.1056/NEJMoa043330
Scoccianti S, Detti B, Sardaro A, Iannalfi A, Meattini I, Leonulli BG et al (2008) Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs 19(6):613–620. doi:10.1097/CAD.0b013e3283005075
Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J, Weller M (2006) PCV chemotherapy for recurrent glioblastoma. Neurology 66(4):587–589. doi:10.1212/01.wnl.0000197792.73656.c2
De Groot JF, Yung WK (2008) Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 14(5):279–285
Klar U, Hoffmann J, Giurescu M (2008) Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate. Expert Opin Investig Drugs 17(11):1735–1748. doi:10.1517/13543784.17.11.1735
Hoffmann J, Fichtner I, Lemm M, Lienau P, Hess-Stumpp H, Rotgeri A, Hofmann B, Klar U (2008) Sagopilone crosses the blood–brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol 11(2):158–166. doi:10.1215/15228517-2008-072
Hoffmann J, Vitale I, Buchmann B, Galluzzi L, Schwede W, Senovilla L et al (2008) Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res 68(13):5301–5308. doi:10.1158/0008-5472.CAN-08-0237
Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280
Vasey PA, Paul J, Birt A, Junor EJ, Reed NS, Symonds RP et al (1999) Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group. J Clin Oncol 17(7):2069–2080
Durmaz R, Erken S, Arslantaş A, Atasoy MA, Bal C, Tel E (1997) Management of glioblastoma multiforme: with special reference to recurrence. Clin Neurol Neurosurg 99:117–123. doi:10.1016/S0303-8467(97)00014-0
Pronzato P (2008) New therapeutic options for chemotherapy-resistant metastatic breast cancer: the epothilones. Drugs 68(2):139–146. doi:10.2165/00003495-200868020-00001 (review)
Dietzmann A, Kanakis D, Kirches E, Kropf S, Mawrin C, Dietzmann K (2003) Nanomolar concentrations of epothilone D inhibit the proliferation of glioma cells and severely affect their tubulin cytoskeleton. J Neurooncol 65(2):99–106. doi:10.1023/B:NEON.0000003679.40609.63
Klar U, Buchmann B, Schwede W, Skuballa W, Hoffmann J, Lichtner RB (2006) Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl 45:7942–7948. doi:10.1002/anie.200602785
Stupp R, Tosoni A, Taal W, Hau P, Campone M, Gijtenbeek J et al (2008) Phase II trial of the epothilone analog sagopilone (ZK219477; ZK EPO) in patients with recurrent glioblastoma: initial report of the EORTC study 26061. J Clin Oncol. ASCO annual meeting proceedings (post-meeting edition), vol 26, No. 15S (May 20 Supplement), 2008: 2015
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Silvani, A., Gaviani, P., Fiumani, A. et al. Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. J Neurooncol 95, 61–64 (2009). https://doi.org/10.1007/s11060-009-9890-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-009-9890-8